{
    "abstract": "Aims: To investigate the effect of Glu-3 OXM-like analogues on food intake and bodyweight in male rats. Background: Oxyntomodulin (OXM) is a natural agonist at both the glucagon receptor (GCGr) and the glucagon-like peptide 1 receptor (GLP-1r), and peripheral administration reduces food intake and increases energy expenditure in rodents and humans. Substituting the native glutamine (Gln) at amino acid position 3 of OXM for glutamate (Glu) has previously been shown to diminish GCGr activity without affecting GLP-1r activity. The effects of Glu-3 OXM analogues have not been investigated in rats. Methods: The effect of 2 Glu-3-substituted OXM-like analogues (eg, OXM14E3 and OXM15E3) on food intake and body weight was investigated in male Wistar rats during 6 days of daily subcutaneous (SC) administration. The effects of Glu-3 substitution on analogue binding and activity at the rat GCGr and rat GLP-1 receptor were investigated in vitro using Chinese hamster ovary or Chinese hamster lung cells. Results: We report the novel finding that 2 5-nmol/kg Glu-3 OXM-like analogues (OXM14E3 and OXM15E3) significantly increased rat body weight by up to 4% compared with the equivalent non-Glu-3 analogues (OXM14 and OXM15), without affecting food intake. The effect of OXM15E3 on body weight was dose-dependent. Glu-3 analogues, including Glu-3 OXM, decreased glucagon-mediated cyclic adenosine monophosphate accumulation in Chinese hamster ovary cells expressing the rat GCGr, suggesting they may be acting as antagonists. Conclusions: The results indicate Glu-3 OXM-like analogues might not be suitable tools to investigate the mechanism of OXM analogue action in a rat model because they significantly increase body weight independent of food intake. Glu-3 OXM analogues are partial agonists at the rat GCGr and may also act as antagonists, possibly resulting in the observed increase in body weight.",
    "bib_entries": {
        "bib1": {
            "authors": [
                {
                    "first": "Barry D.",
                    "initial": "B.D.",
                    "last": "Kerr"
                },
                {
                    "first": "Peter R.",
                    "initial": "P.R.",
                    "last": "Flatt"
                },
                {
                    "first": "Victor A.",
                    "initial": "V.A.",
                    "last": "Gault"
                }
            ],
            "doi": "10.1016/j.bcp.2010.08.010",
            "firstpage": "1727",
            "issn": "00062952",
            "lastpage": "1735",
            "pmid": "20735990",
            "pub_year": 2010,
            "title": "(d-Ser2)Oxm[mPEG-PAL]: A novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions",
            "volume": "80"
        },
        "bib10": {
            "authors": [
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Ratner"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Nauck"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Kapitza"
                },
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "Asnaghi"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Boldrin"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Balena"
                }
            ],
            "doi": "10.1111/j.1464-5491.2010.02990.x",
            "firstpage": "556",
            "issn": "07423071",
            "lastpage": "562",
            "pmid": "20536952",
            "pub_year": 2010,
            "title": "Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: A randomized double-blind placebo-controlled study",
            "volume": "27"
        },
        "bib11": {
            "authors": [
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "O'Shea"
                },
                {
                    "first": "D. G.A.",
                    "initial": "D.G.A.",
                    "last": "Morgan"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Meeran"
                },
                {
                    "first": "C. M.B.",
                    "initial": "C.M.B.",
                    "last": "Edwards"
                },
                {
                    "first": "M. D.",
                    "initial": "M.D.",
                    "last": "Turton"
                },
                {
                    "first": "S. J.",
                    "initial": "S.J.",
                    "last": "Choi"
                },
                {
                    "first": "M. M.",
                    "initial": "M.M.",
                    "last": "Heath"
                },
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Gunn"
                },
                {
                    "first": "G. M.",
                    "initial": "G.M.",
                    "last": "Taylor"
                },
                {
                    "first": "J. K.",
                    "initial": "J.K.",
                    "last": "Howard"
                },
                {
                    "first": "C. I.",
                    "initial": "C.I.",
                    "last": "Bloom"
                },
                {
                    "first": "C. J.",
                    "initial": "C.J.",
                    "last": "Small"
                },
                {
                    "first": "O.",
                    "initial": "O.",
                    "last": "Haddo"
                },
                {
                    "first": "J. J.",
                    "initial": "J.J.",
                    "last": "Ma"
                },
                {
                    "first": "W.",
                    "initial": "W.",
                    "last": "Callinan"
                },
                {
                    "first": "D. M.",
                    "initial": "D.M.",
                    "last": "Smith"
                },
                {
                    "first": "M. A.",
                    "initial": "M.A.",
                    "last": "Ghatei"
                },
                {
                    "first": "S. R.",
                    "initial": "S.R.",
                    "last": "Bloom"
                }
            ],
            "doi": "10.1210/endo.138.1.4899",
            "firstpage": "196",
            "issn": "00137227",
            "lastpage": "202",
            "pmid": "8977404",
            "pub_year": 1997,
            "title": "Neuropeptide Y induced feeding in the rat is mediated by a novel receptor",
            "volume": "138"
        },
        "bib12": null,
        "bib13": {
            "authors": [
                {
                    "first": "Tricia M.",
                    "initial": "T.M.",
                    "last": "Tan"
                },
                {
                    "first": "Benjamin C.T.",
                    "initial": "B.C.T.",
                    "last": "Field"
                },
                {
                    "first": "Katherine A.",
                    "initial": "K.A.",
                    "last": "McCullough"
                },
                {
                    "first": "Rachel C.",
                    "initial": "R.C.",
                    "last": "Troke"
                },
                {
                    "first": "Edward S.",
                    "initial": "E.S.",
                    "last": "Chambers"
                },
                {
                    "first": "Victoria",
                    "initial": "V.",
                    "last": "Salem"
                },
                {
                    "first": "Juan Gonzalez",
                    "initial": "J.G.",
                    "last": "Maffe"
                },
                {
                    "first": "Kevin C.R.",
                    "initial": "K.C.R.",
                    "last": "Baynes"
                },
                {
                    "first": "Akila",
                    "initial": "A.",
                    "last": "De Silva"
                },
                {
                    "first": "Alexander",
                    "initial": "A.",
                    "last": "Viardot"
                },
                {
                    "first": "Ali",
                    "initial": "A.",
                    "last": "Alsafi"
                },
                {
                    "first": "Gary S.",
                    "initial": "G.S.",
                    "last": "Frost"
                },
                {
                    "first": "Mohammad A.",
                    "initial": "M.A.",
                    "last": "Ghatei"
                },
                {
                    "first": "Stephen R.",
                    "initial": "S.R.",
                    "last": "Bloom"
                }
            ],
            "doi": "10.2337/db12-0797",
            "firstpage": "1131",
            "issn": "00121797",
            "lastpage": "1138",
            "pmid": "23248172",
            "pub_year": 2013,
            "title": "Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia",
            "volume": "62"
        },
        "bib14": {
            "authors": [
                {
                    "first": "C. J.",
                    "initial": "C.J.",
                    "last": "Billington"
                },
                {
                    "first": "J. E.",
                    "initial": "J.E.",
                    "last": "Briggs"
                },
                {
                    "first": "J. G.",
                    "initial": "J.G.",
                    "last": "Link"
                },
                {
                    "first": "A. S.",
                    "initial": "A.S.",
                    "last": "Levine"
                }
            ],
            "firstpage": "R501",
            "issn": "00029513",
            "lastpage": "R507",
            "pmid": "1877708",
            "pub_year": 1991,
            "title": "Glucagon in physiological concentrations stimulates brown fat thermogenesis in vivo",
            "volume": "261"
        },
        "bib15": {
            "authors": [
                {
                    "first": "A. H.",
                    "initial": "A.H.",
                    "last": "Sparre-Ulrich"
                },
                {
                    "first": "L. S.",
                    "initial": "L.S.",
                    "last": "Hansen"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Svendsen"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Christensen"
                },
                {
                    "first": "F. K.",
                    "initial": "F.K.",
                    "last": "Knop"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Hartmann"
                },
                {
                    "first": "J. J.",
                    "initial": "J.J.",
                    "last": "Holst"
                },
                {
                    "first": "M. M.",
                    "initial": "M.M.",
                    "last": "Rosenkilde"
                }
            ],
            "doi": "10.1111/bph.13323",
            "firstpage": "27",
            "issn": "00071188",
            "lastpage": "38",
            "pmid": "26359804",
            "pub_year": 2016,
            "title": "Species-specific action of (Pro3)GIP - A full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors",
            "volume": "173"
        },
        "bib2": {
            "authors": [
                {
                    "first": "J. J.",
                    "initial": "J.J.",
                    "last": "Holst"
                }
            ],
            "doi": "10.1146/annurev.physiol.59.1.257",
            "firstpage": "257",
            "issn": "00664278",
            "lastpage": "271",
            "pmid": "9074764",
            "pub_year": 1997,
            "title": "Enteroglucagon",
            "volume": "59"
        },
        "bib3": {
            "authors": [
                {
                    "first": "Catherine L.",
                    "initial": "C.L.",
                    "last": "Dakin"
                },
                {
                    "first": "Caroline J.",
                    "initial": "C.J.",
                    "last": "Small"
                },
                {
                    "first": "Rachel L.",
                    "initial": "R.L.",
                    "last": "Batterham"
                },
                {
                    "first": "Nicola M.",
                    "initial": "N.M.",
                    "last": "Neary"
                },
                {
                    "first": "Mark A.",
                    "initial": "M.A.",
                    "last": "Cohen"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Patterson"
                },
                {
                    "first": "Mohammad A.",
                    "initial": "M.A.",
                    "last": "Ghatei"
                },
                {
                    "first": "Stephen R.",
                    "initial": "S.R.",
                    "last": "Bloom"
                }
            ],
            "doi": "10.1210/en.2003-1338",
            "firstpage": "2687",
            "issn": "00137227",
            "lastpage": "2695",
            "pmid": "15001546",
            "pub_year": 2004,
            "title": "Peripheral oxyntomodulin reduces food intake and body weight gain in rats",
            "volume": "145"
        },
        "bib4": {
            "authors": [
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Wynne"
                },
                {
                    "first": "A. J.",
                    "initial": "A.J.",
                    "last": "Park"
                },
                {
                    "first": "C. J.",
                    "initial": "C.J.",
                    "last": "Small"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Meeran"
                },
                {
                    "first": "M. A.",
                    "initial": "M.A.",
                    "last": "Ghatei"
                },
                {
                    "first": "G. S.",
                    "initial": "G.S.",
                    "last": "Frost"
                },
                {
                    "first": "S. R.",
                    "initial": "S.R.",
                    "last": "Bloom"
                }
            ],
            "doi": "10.1038/sj.ijo.0803344",
            "firstpage": "1729",
            "issn": "03070565",
            "lastpage": "1736",
            "pmid": "16619056",
            "pub_year": 2006,
            "title": "Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: A randomised controlled trial",
            "volume": "30"
        },
        "bib5": {
            "authors": [
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Kervran"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Dubrasquet"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Blache"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Martinez"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Bataille"
                }
            ],
            "doi": "10.1016/0167-0115(90)90194-2",
            "firstpage": "41",
            "issn": "01670115",
            "lastpage": "52",
            "pmid": "2270317",
            "pub_year": 1990,
            "title": "Metabolic clearance rates of oxyntomodulin and glucagon in the rat: contribution of the kidney",
            "volume": "31"
        },
        "bib6": {
            "authors": [
                {
                    "first": "Alessandro",
                    "initial": "A.",
                    "last": "Pocai"
                },
                {
                    "first": "Paul E.",
                    "initial": "P.E.",
                    "last": "Carrington"
                },
                {
                    "first": "Jennifer R.",
                    "initial": "J.R.",
                    "last": "Adams"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Wright"
                },
                {
                    "first": "George",
                    "initial": "G.",
                    "last": "Eiermann"
                },
                {
                    "first": "Lan",
                    "initial": "L.",
                    "last": "Zhu"
                },
                {
                    "first": "Xiaobing",
                    "initial": "X.",
                    "last": "Du"
                },
                {
                    "first": "Aleksandr",
                    "initial": "A.",
                    "last": "Petrov"
                },
                {
                    "first": "Michael E.",
                    "initial": "M.E.",
                    "last": "Lassman"
                },
                {
                    "first": "Guoqiang",
                    "initial": "G.",
                    "last": "Jiang"
                },
                {
                    "first": "Franklin",
                    "initial": "F.",
                    "last": "Liu"
                },
                {
                    "first": "Corey",
                    "initial": "C.",
                    "last": "Miller"
                },
                {
                    "first": "Laurie M.",
                    "initial": "L.M.",
                    "last": "Tota"
                },
                {
                    "first": "Gaochao",
                    "initial": "G.",
                    "last": "Zhou"
                },
                {
                    "first": "Xiaoping",
                    "initial": "X.",
                    "last": "Zhang"
                },
                {
                    "first": "Michael M.",
                    "initial": "M.M.",
                    "last": "Sountis"
                },
                {
                    "first": "Alessia",
                    "initial": "A.",
                    "last": "Santoprete"
                },
                {
                    "first": "Elena",
                    "initial": "E.",
                    "last": "Capito'"
                },
                {
                    "first": "Gary G.",
                    "initial": "G.G.",
                    "last": "Chicchi"
                },
                {
                    "first": "Nancy",
                    "initial": "N.",
                    "last": "Thornberry"
                },
                {
                    "first": "Elisabetta",
                    "initial": "E.",
                    "last": "Bianchi"
                },
                {
                    "first": "Antonello",
                    "initial": "A.",
                    "last": "Pessi"
                },
                {
                    "first": "Donald J.",
                    "initial": "D.J.",
                    "last": "Marsh"
                },
                {
                    "first": "Ranabir",
                    "initial": "R.",
                    "last": "SinhaRoy"
                }
            ],
            "doi": "10.2337/db09-0278",
            "firstpage": "2258",
            "issn": "00121797",
            "lastpage": "2266",
            "pmid": "19602537",
            "pub_year": 2009,
            "title": "Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice",
            "volume": "58"
        },
        "bib7": {
            "authors": [
                {
                    "first": "Jennifer R.",
                    "initial": "J.R.",
                    "last": "Kosinski"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Hubert"
                },
                {
                    "first": "Paul E.",
                    "initial": "P.E.",
                    "last": "Carrington"
                },
                {
                    "first": "Gary G.",
                    "initial": "G.G.",
                    "last": "Chicchi"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Mu."
                },
                {
                    "first": "Corey",
                    "initial": "C.",
                    "last": "Miller"
                },
                {
                    "first": "Jin",
                    "initial": "J.",
                    "last": "Cao"
                },
                {
                    "first": "Elisabetta",
                    "initial": "E.",
                    "last": "Bianchi."
                },
                {
                    "first": "Antonello",
                    "initial": "A.",
                    "last": "Pessi"
                },
                {
                    "first": "Ranabir",
                    "initial": "R.",
                    "last": "Sinharoy"
                },
                {
                    "first": "Donald J.",
                    "initial": "D.J.",
                    "last": "Marsh"
                },
                {
                    "first": "Alessandro",
                    "initial": "A.",
                    "last": "Pocai"
                }
            ],
            "doi": "10.1038/oby.2012.67",
            "firstpage": "1566",
            "issn": "19307381",
            "lastpage": "1571",
            "pmid": "22421924",
            "pub_year": 2012,
            "title": "The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin",
            "volume": "20"
        },
        "bib8": {
            "authors": [
                {
                    "first": "Xiaobing",
                    "initial": "X.",
                    "last": "Du"
                },
                {
                    "first": "Jennifer R.",
                    "initial": "J.R.",
                    "last": "Kosinski"
                },
                {
                    "first": "Julie",
                    "initial": "J.",
                    "last": "Lao"
                },
                {
                    "first": "Xiaolan",
                    "initial": "X.",
                    "last": "Shen"
                },
                {
                    "first": "Aleksandr",
                    "initial": "A.",
                    "last": "Petrov"
                },
                {
                    "first": "Gary G.",
                    "initial": "G.G.",
                    "last": "Chicchi"
                },
                {
                    "first": "George J.",
                    "initial": "G.J.",
                    "last": "Eiermann"
                },
                {
                    "first": "Alessandro",
                    "initial": "A.",
                    "last": "Pocai"
                }
            ],
            "doi": "10.1152/ajpendo.00142.2012",
            "firstpage": "E265",
            "issn": "01931849",
            "lastpage": "E271",
            "pmid": "22621866",
            "pub_year": 2012,
            "title": "Differential effects of oxyntomodulin and GLP-1 on glucose metabolism",
            "volume": "303"
        },
        "bib9": {
            "authors": [
                {
                    "first": "Raymond T.",
                    "initial": "R.T.",
                    "last": "Bartus"
                },
                {
                    "first": "Mark A.",
                    "initial": "M.A.",
                    "last": "Tracy"
                },
                {
                    "first": "Dwaine F.",
                    "initial": "D.F.",
                    "last": "Emerich"
                },
                {
                    "first": "Stephen E.",
                    "initial": "S.E.",
                    "last": "Zale"
                }
            ],
            "firstpage": "1161",
            "issn": "00368075",
            "lastpage": "1162",
            "pmid": "9735031",
            "pub_year": 1998,
            "title": "Sustained delivery of proteins for novel therapeutic products",
            "volume": "281"
        }
    },
    "body_text": [
        {
            "endOffset": 12244,
            "parents": [],
            "refoffsets": {
                "bib6": {
                    "endOffset": 12244,
                    "startOffset": 12241
                },
                "bib7": {
                    "endOffset": 12244,
                    "startOffset": 12241
                }
            },
            "secId": "s0005",
            "sentence": "Previous results indicate that OXM activity at the GLP-1r is responsible for the reduction in food intake and activity at the GCGr increases energy expenditure.6,7",
            "startOffset": 12081,
            "title": "Introduction"
        },
        {
            "endOffset": 14223,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "These analogues were chosen for investigation because they had similar pharmacokinetic profiles but different affinity and potency at the rat glucagon and GLP-1rs.",
            "startOffset": 14060,
            "title": "Compounds"
        },
        {
            "endOffset": 20551,
            "parents": [],
            "refoffsets": {
                "bib2": {
                    "endOffset": 20551,
                    "startOffset": 20550
                }
            },
            "secId": "s0065",
            "sentence": "Structurally, OXM is the 29 amino acids of glucagon with a C-terminal octapeptide tail.2",
            "startOffset": 20463,
            "title": "Discussion"
        },
        {
            "endOffset": 18363,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Differences in cumulative food intake and body weight were analyzed using 1-way ANOVA and post hoc tests with Dunnett or Bonferroni correction (Prism version 5 software).",
            "startOffset": 18193,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 23027,
            "parents": [],
            "refoffsets": {
                "bib6": {
                    "endOffset": 23027,
                    "startOffset": 23024
                },
                "bib7": {
                    "endOffset": 23027,
                    "startOffset": 23024
                }
            },
            "secId": "s0065",
            "sentence": "The increase in body weight following Glu-3 administration may be a rat-specific phenomenon, as previous results with Glu-3 OXM-like peptides were obtained in mice and did not show an increase.6,7",
            "startOffset": 22831,
            "title": "Discussion"
        },
        {
            "endOffset": 16086,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Levels of cAMP accumulation was measured in Chinese hamster ovary-K1 cells overexpressing the rat GCGr (cDNA from Origene, Cambridge Bioscience, Cambridge, United Kingdom) or Chinese hamster lung cells overexpressing the rat GLP-1r (a gift from Bernard Thorens, University of Lausanne, Switzerland).",
            "startOffset": 15787,
            "title": "In vitro cyclic adenosine monophosphate (cAMP) accumulation"
        },
        {
            "endOffset": 10947,
            "parents": [],
            "refoffsets": {
                "bib1": {
                    "endOffset": 10947,
                    "startOffset": 10946
                }
            },
            "secId": "s0005",
            "sentence": "The gut-derived hormone oxyntomodulin (OXM) is a naturally occurring dual agonist of both the glucagon receptor (GCGr) and glucagons-like peptide 1 receptor (GLP-1r).1",
            "startOffset": 10780,
            "title": "Introduction"
        },
        {
            "endOffset": 18427,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "In all cases P < 0.05 was considered statistically significant.",
            "startOffset": 18364,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 16288,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Cells were seeded in a 48-well plate (Nunc, VWR International Inc, Chicago, Illinois) in their respective supplemented DMEM, at a density of 37,500 cells/well (250 \u00b5L/well), then incubated for 24 hours.",
            "startOffset": 16086,
            "title": "In vitro cyclic adenosine monophosphate (cAMP) accumulation"
        },
        {
            "endOffset": 19513,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Receptor binding affinity for the Glu-3 analogues at the rat GLP-1r was 2.7- to 4.4-fold greater than their Glu-3 counterparts (Figure 3D).",
            "startOffset": 19374,
            "title": "In vitro"
        },
        {
            "endOffset": 14675,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "All animal procedures were approved under the British Home Office Animals (Scientific Procedures) Act 1986 (Project Licence 70/7236).",
            "startOffset": 14542,
            "title": "Animals"
        },
        {
            "endOffset": 19373,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "At the rat GCGr the binding affinity of the Glu-3 substituted peptides OXM14E3 and OXM15E3 was 63-fold and 120-fold lower compared with OXM14 and OXM15, respectively (Figure 3D).",
            "startOffset": 19195,
            "title": "In vitro"
        },
        {
            "endOffset": 20349,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Except 30 nM, all concentrations of OXME3 tested decreased glucagon-mediated cAMP accumulation by a mean of 40.3% (Figure 3C).",
            "startOffset": 20223,
            "title": "In vitro"
        },
        {
            "endOffset": 17234,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "cAMP levels were measured using an indirect ELISA according to the manufacturer\u2019s instructions (ADI-900-066, Enzo Life Sciences, United Kingdom), optical density was read at 405 nm on a Biotek ELx808 (Wolf Laboratories, York, United Kingdom).",
            "startOffset": 16992,
            "title": "In vitro cyclic adenosine monophosphate (cAMP) accumulation"
        },
        {
            "endOffset": 17782,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Membranes (100 \u00b5g protein) were incubated in siliconized polypropylene tubes with 100 pm (500 Bq) either iodine125 labeled GLP-1 or iodine125 labeled glucagon in competition with unlabeled peptide.",
            "startOffset": 17585,
            "title": "In vitro receptor binding: Supplementary"
        },
        {
            "endOffset": 16991,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Postincubation, medium was removed and cells lysed with 120 \u00b5L/well of 0.1 M hydrochloride + 0.5% nonionic, octylphenol ethoxylate surfactant.",
            "startOffset": 16849,
            "title": "In vitro cyclic adenosine monophosphate (cAMP) accumulation"
        },
        {
            "endOffset": 23481,
            "parents": [],
            "refoffsets": {
                "bib15": {
                    "endOffset": 23194,
                    "startOffset": 23192
                }
            },
            "secId": "s0065",
            "sentence": "A recently published study15 demonstrated that analogues of glucose-dependent insulinotropic polypeptide (GIP) with a proline substitution at amino acid position 3 (Pro-3) were full agonists at the human GIP receptor and partial agonists that could acts as competitive antagonists at the rat and mouse GIP receptor.",
            "startOffset": 23166,
            "title": "Discussion"
        },
        {
            "endOffset": 13352,
            "parents": [],
            "secId": "s0005",
            "sentence": "The results of our study suggest that Glu-3-substituted OXM analogues may be partial agonists that can act as competitive antagonists in vitro and increase body weight independent of food intake in vivo.",
            "startOffset": 13149,
            "title": "Introduction"
        },
        {
            "endOffset": 15181,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "All cell culture reagents were obtained from Invitrogen (Life Technologies Ltd, Paisley, United Kingdom) unless otherwise stated.",
            "startOffset": 15052,
            "title": "Cell culture"
        },
        {
            "endOffset": 20031,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Concentrations of 0.03 to 1 nM OXM14E3 (Figure 3A) and 0.03 to 0.3 nM OXM15E3 (Figure 3B) decreased the percentage of glucagon-mediated cAMP production at the rat GCGr by a mean of 18.4% and 27.5%, respectively.",
            "startOffset": 19820,
            "title": "In vitro"
        },
        {
            "endOffset": 12936,
            "parents": [],
            "secId": "s0005",
            "sentence": "Our pilot experiments suggested that Glu-3 OXM-like analogues increased body weight in rats without affecting food intake; therefore, further experiments were undertaken to clarify these findings.",
            "startOffset": 12740,
            "title": "Introduction"
        },
        {
            "endOffset": 17940,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Total specific binding was calculated as the difference in counts between assays in the presence (nonspecific) and absence (total) of up to 6000 nM peptides.",
            "startOffset": 17783,
            "title": "In vitro receptor binding: Supplementary"
        },
        {
            "endOffset": 11905,
            "parents": [],
            "refoffsets": {
                "bib6": {
                    "endOffset": 11816,
                    "startOffset": 11813
                },
                "bib7": {
                    "endOffset": 11816,
                    "startOffset": 11813
                }
            },
            "secId": "s0005",
            "sentence": "Alternatively, substituting glutamine at position 3 of OXM with Glu has previously been reported to diminish GCGr activity without affecting GLP-1r activity,6,7 enabling investigation of mechanisms of action relating to exogenous OXM administration.",
            "startOffset": 11656,
            "title": "Introduction"
        },
        {
            "endOffset": 11363,
            "parents": [],
            "refoffsets": {
                "bib5": {
                    "endOffset": 11295,
                    "startOffset": 11294
                }
            },
            "secId": "s0005",
            "sentence": "Due to the short in vivo half-life of native OXM,5 it is necessary to produce long-lasting analogues for clinical use.",
            "startOffset": 11245,
            "title": "Introduction"
        },
        {
            "endOffset": 21438,
            "parents": [],
            "refoffsets": {
                "bib6": {
                    "endOffset": 21356,
                    "startOffset": 21353
                },
                "bib7": {
                    "endOffset": 21356,
                    "startOffset": 21353
                },
                "bib8": {
                    "endOffset": 21356,
                    "startOffset": 21353
                }
            },
            "secId": "s0065",
            "sentence": "Several previous studies have used Glu-3 analogues to explore the metabolic effects of OXM administration in mice, reporting that GCGr activity was necessary for,6\u20138 but the effect of Glu-3 peptide administration in rats has not been investigated.",
            "startOffset": 21191,
            "title": "Discussion"
        },
        {
            "endOffset": 23681,
            "parents": [],
            "secId": "s0065",
            "sentence": "However, the agonist or antagonist properties of Glu-3 analogues at the mouse and human GCGrs have not been fully investigated.",
            "startOffset": 23554,
            "title": "Discussion"
        },
        {
            "endOffset": 19587,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Substituting Glu at position 3 decreased peptide efficacy at the rat GCGr.",
            "startOffset": 19513,
            "title": "In vitro"
        },
        {
            "endOffset": 17292,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Data were plotted and in vivo efficacy values calculated.",
            "startOffset": 17235,
            "title": "In vitro cyclic adenosine monophosphate (cAMP) accumulation"
        },
        {
            "endOffset": 16749,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "For rat GCGr antagonism studies, cells were incubated for 30 minutes with peptide concentrations diluted in serum-free DMEM with 1 mM IBMX and 0.1 nM glucagon.",
            "startOffset": 16590,
            "title": "In vitro cyclic adenosine monophosphate (cAMP) accumulation"
        },
        {
            "endOffset": 11035,
            "parents": [],
            "refoffsets": {
                "bib2": {
                    "endOffset": 11035,
                    "startOffset": 11034
                }
            },
            "secId": "s0005",
            "sentence": "Structurally OXM is the 29 amino acids of glucagon with a C-terminal octapeptide tail.2",
            "startOffset": 10948,
            "title": "Introduction"
        },
        {
            "endOffset": 12365,
            "parents": [],
            "secId": "s0005",
            "sentence": "Previous work in our lab designed OXM-like dual analogues of the GCGr and GLP-1r based on the 29 amino acids of glucagon.",
            "startOffset": 12244,
            "title": "Introduction"
        },
        {
            "endOffset": 18647,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Daily administration of 25 nmol/kg OXM14E3 to rats significantly increased body weight over 7 days (27.5 [2.2] g; P < 0.01) compared with vehicle controls (11.4 [2.6] g) and OXM14 (9.2 [3.8] g) (Figure 2B).",
            "startOffset": 18441,
            "title": "In vivo"
        },
        {
            "endOffset": 14059,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Both analogues had additional amino acids at residues 30 and 31 and OXM15E3 was C-terminally amidated (Figure 1).",
            "startOffset": 13946,
            "title": "Compounds"
        },
        {
            "endOffset": 13737,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "All peptides (human glucagon, GLP-1, and OXM; analogues OXM14 and OXM15 and their respective Glu-3 analogues OXM14E3 and OXM15E3; and OXME3) were custom synthesized by Insight Biotechnology Limited (Middlesex, United Kingdom) and were >90% pure.",
            "startOffset": 13492,
            "title": "Compounds"
        },
        {
            "endOffset": 21190,
            "parents": [],
            "secId": "s0065",
            "sentence": "These GLP-1r selective Glu-3 peptides offer an alternative method for investigating the contribution of GCGr and GLP-1r activity to the metabolic effects of OXM and related analogues.",
            "startOffset": 21007,
            "title": "Discussion"
        },
        {
            "endOffset": 18192,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "cAMP in vitro efficacy and binding in vitro affinity were calculated using nonlinear regression with Prism version 5 software (GraphPad Software Inc, San Diego, California).",
            "startOffset": 18019,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 16849,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Five wells of each concentration and 12 wells of 0.1 nM glucagon alone were applied per experiment.",
            "startOffset": 16750,
            "title": "In vitro cyclic adenosine monophosphate (cAMP) accumulation"
        },
        {
            "endOffset": 17584,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Briefly, membranes were prepared from Chinese hamster ovary-K1 cells overexpressing the rat GCGr or Chinese hamster lung cells overexpressing the rat GLP-1r by osmotic lysis and differential centrifugation.",
            "startOffset": 17378,
            "title": "In vitro receptor binding: Supplementary"
        },
        {
            "endOffset": 12080,
            "parents": [],
            "refoffsets": {
                "bib6": {
                    "endOffset": 12080,
                    "startOffset": 12079
                },
                "bib7": {
                    "endOffset": 12051,
                    "startOffset": 12048
                },
                "bib8": {
                    "endOffset": 12051,
                    "startOffset": 12048
                }
            },
            "secId": "s0005",
            "sentence": "These Glu-3 OXM analogues have been used in mice to investigate the contribution of GCGr and GLP-1r activity to the function of both native OXM7,8 and a derivatized analogue.6",
            "startOffset": 11905,
            "title": "Introduction"
        },
        {
            "endOffset": 15543,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Chinese hamster ovary-K1 cells overexpressing the rat GCGr were routinely maintained in Dulbecco\u2019s modified eagle medium (DMEM) with 25 mM glucose and 1 mM sodium pyruvate supplemented with 10% fetal bovine serum, 25 mM hydroxyethyl piperazineethanesulfonic acid, 1% antibiotic (100 U/mL penicillin and 100 \u00b5g/mL streptomycin), and 1 \u00d7 nonessential amino acids.",
            "startOffset": 15182,
            "title": "Cell culture"
        },
        {
            "endOffset": 22248,
            "parents": [],
            "refoffsets": {
                "bib12": {
                    "endOffset": 22163,
                    "startOffset": 22158
                },
                "bib13": {
                    "endOffset": 22163,
                    "startOffset": 22158
                },
                "bib14": {
                    "endOffset": 22248,
                    "startOffset": 22246
                }
            },
            "secId": "s0065",
            "sentence": "Glucagon administration increases energy expenditure12,13 and in rodents this is postulated to be due to activation of brown adipose tissue.14",
            "startOffset": 22106,
            "title": "Discussion"
        },
        {
            "endOffset": 15728,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Chinese hamster lung cells overexpressing the rat GLP-1r were maintained in the same DMEM but without additional hydroxyethyl piperazineethanesulfonic acid or nonessential amino acids.",
            "startOffset": 15544,
            "title": "Cell culture"
        },
        {
            "endOffset": 22631,
            "parents": [],
            "secId": "s0065",
            "sentence": "Glu-3 OXM analogues may antagonize the activity of endogenous glucagon, possibly causing a reduction in energy expenditure and resulting in the observed increase in rat body weight.",
            "startOffset": 22450,
            "title": "Discussion"
        },
        {
            "endOffset": 24274,
            "parents": [],
            "secId": "s0070",
            "sentence": "OXM-like analogues with a Glu-3 substitution significantly increase body weight in a rat model, independent of food intake.",
            "startOffset": 24151,
            "title": "Conclusions"
        },
        {
            "endOffset": 14815,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Before study commencement, rats were randomized to treatment groups with equal mean body weights.",
            "startOffset": 14718,
            "title": "In vivo food intake and body weight studies"
        },
        {
            "endOffset": 11655,
            "parents": [],
            "secId": "s0005",
            "sentence": "Using GCGr or GLP-1r antagonists can interfere with the actions of endogenous glucagon and GLP-1, hormones that play critical roles in glucose homeostasis, giving an inaccurate picture of OXM actions.",
            "startOffset": 11455,
            "title": "Introduction"
        },
        {
            "endOffset": 23553,
            "parents": [],
            "secId": "s0065",
            "sentence": "It is possible this may also be the case with Glu-3 OXM-like analogues.",
            "startOffset": 23482,
            "title": "Discussion"
        },
        {
            "endOffset": 18805,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Daily 25 nmol/kg OXM15E3 administration significantly increased body weight over 7 days (19 [3.3] g; P < 0.01) compared with OXM15 (4.5 [2.7] g) (Figure 2B).",
            "startOffset": 18648,
            "title": "In vivo"
        },
        {
            "endOffset": 22449,
            "parents": [],
            "refoffsets": {
                "bib3": {
                    "endOffset": 22362,
                    "startOffset": 22357
                },
                "bib4": {
                    "endOffset": 22362,
                    "startOffset": 22357
                },
                "bib6": {
                    "endOffset": 22449,
                    "startOffset": 22446
                },
                "bib7": {
                    "endOffset": 22449,
                    "startOffset": 22446
                }
            },
            "secId": "s0065",
            "sentence": "Exogenous peripheral administration of native OXM or long-acting analogues also increases energy expenditure3,4,6 and several murine studies have suggested a GCGr-mediated mechanism is responsible.6,7",
            "startOffset": 22249,
            "title": "Discussion"
        },
        {
            "endOffset": 17377,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "bib11": {
                    "endOffset": 17355,
                    "startOffset": 17353
                }
            },
            "secId": "s0040",
            "sentence": "Refer to O\u2019Shea et al11 for detailed methods.",
            "startOffset": 17332,
            "title": "In vitro receptor binding: Supplementary"
        },
        {
            "endOffset": 19820,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Glu-3 substitution increased rat GLP-1r efficacy by 1.2- to 1.6-fold (Figure 3D).",
            "startOffset": 19739,
            "title": "In vitro"
        },
        {
            "endOffset": 24390,
            "parents": [],
            "secId": "s0070",
            "sentence": "Glu-3 analogues appear to be partial agonists at the rat GCGr and can also act as competitive antagonists in vitro.",
            "startOffset": 24275,
            "title": "Conclusions"
        },
        {
            "endOffset": 12578,
            "parents": [],
            "secId": "s0005",
            "sentence": "A number of conservative amino acid substitutions were made to increase GLP-1r activity, improve peptide stability, and extended circulatory half-life, with a view to developing a potential treatment for obesity.",
            "startOffset": 12366,
            "title": "Introduction"
        },
        {
            "endOffset": 17999,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Data were plotted and in vitro affinity values calculated.",
            "startOffset": 17941,
            "title": "In vitro receptor binding: Supplementary"
        },
        {
            "endOffset": 20814,
            "parents": [],
            "secId": "s0065",
            "sentence": "The dual agonist activity of OXM at the GCGr and GLP-1r makes it difficult to investigate the mechanisms involved in the weight-reducing effects of exogenous OXM administration because receptor antagonists also block the actions of endogenous glucagon and GLP-1.",
            "startOffset": 20552,
            "title": "Discussion"
        },
        {
            "endOffset": 11244,
            "parents": [],
            "refoffsets": {
                "bib3": {
                    "endOffset": 11244,
                    "startOffset": 11241
                },
                "bib4": {
                    "endOffset": 11244,
                    "startOffset": 11241
                }
            },
            "secId": "s0005",
            "sentence": "Administration of OXM to rodents and humans reduces food intake and increases energy expenditure, generating significant weight loss and highlighting OXM as a potential pharmacologic treatment for obesity.3,4",
            "startOffset": 11036,
            "title": "Introduction"
        },
        {
            "endOffset": 13945,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The structure of analogues OXM14E3 and OXM15E3 were based on the 29 amino acids of glucagon and, other than the Glu-3 substitution, contained 6 single amino acid substitutions between residues 12 through 29.",
            "startOffset": 13738,
            "title": "Compounds"
        },
        {
            "endOffset": 19738,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The efficacy of OXM14E3, OXM15E3, and OXME3 was 200-, 25-, and 13-fold lower respectively compared with their Glu-3 equivalents OXM14, OXM15, and OXM.",
            "startOffset": 19588,
            "title": "In vitro"
        },
        {
            "endOffset": 21006,
            "parents": [],
            "refoffsets": {
                "bib6": {
                    "endOffset": 21006,
                    "startOffset": 21003
                },
                "bib7": {
                    "endOffset": 21006,
                    "startOffset": 21003
                }
            },
            "secId": "s0065",
            "sentence": "Previously it has been reported that exchanging the position-3 glutamine of OXM or a related analogue for Glu diminishes mouse GCGr activity without affecting activity at the mouse GLP-1r.6,7",
            "startOffset": 20815,
            "title": "Discussion"
        },
        {
            "endOffset": 15040,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "bib10": {
                    "endOffset": 14932,
                    "startOffset": 14928
                },
                "bib9": {
                    "endOffset": 14932,
                    "startOffset": 14928
                }
            },
            "secId": "s0025",
            "sentence": "An injection of peptide (maximum volume 50 \u00b5L, reconstituted in zinc chloride to enhance peptide depot formation9,10) or vehicle (saline) was administered subcutaneously at 1600 hours daily and food and body weight recorded.",
            "startOffset": 14816,
            "title": "In vivo food intake and body weight studies"
        },
        {
            "endOffset": 22831,
            "parents": [],
            "secId": "s0065",
            "sentence": "Investigation of the effects of Glu-3 peptides on energy expenditure in rats is needed.",
            "startOffset": 22744,
            "title": "Discussion"
        },
        {
            "endOffset": 18898,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Food intake was not increased after administration of either OXM14E3 or OXM15E3 (Figure 2A).",
            "startOffset": 18806,
            "title": "In vivo"
        },
        {
            "endOffset": 14541,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Male Wistar rats (Charles River, Margate, United Kingdom) were maintained in individual cages under controlled temperature (21\u00b0C\u201323\u00b0C) and light conditions (12:12 light-dark cycle, lights on at 0700 hours) with ad libitum access to food (RM1 diet; SDS, Witham, United Kingdom) and water unless otherwise stated.",
            "startOffset": 14230,
            "title": "Animals"
        },
        {
            "endOffset": 23881,
            "parents": [],
            "secId": "s0065",
            "sentence": "Additionally, differences in peptide and receptor homology between species may contribute to the differential effects observed with GIP analogues with a proline substitution at amino acid position 3.",
            "startOffset": 23682,
            "title": "Discussion"
        },
        {
            "endOffset": 22743,
            "parents": [],
            "secId": "s0065",
            "sentence": "However endogenous glucagon has not been shown to play a tonic role in energy expenditure or weight regulation.",
            "startOffset": 22632,
            "title": "Discussion"
        },
        {
            "endOffset": 16590,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Each peptide concentration was applied in duplicate or triplicate per experiment.",
            "startOffset": 16509,
            "title": "In vitro cyclic adenosine monophosphate (cAMP) accumulation"
        },
        {
            "endOffset": 19187,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Daily administration of 10 nmol/kg and 20 nmol/kg OXM15E3 resulted in a significant increase in rat body weight over 7 days (15.1 [1.9] g; P < 0.05 and 17.7 [1.5] g; P < 0.01, respectively) compared with vehicle controls (7.9 [2.0] g) (Figure 2D), without altering food intake (Figure 2C).",
            "startOffset": 18898,
            "title": "In vivo"
        },
        {
            "endOffset": 23165,
            "parents": [],
            "refoffsets": {
                "bib6": {
                    "endOffset": 23088,
                    "startOffset": 23085
                },
                "bib7": {
                    "endOffset": 23088,
                    "startOffset": 23085
                }
            },
            "secId": "s0065",
            "sentence": "However the Glu-3 peptides used in these previous studies6,7 were derivatized and administered at higher doses than in the present study.",
            "startOffset": 23028,
            "title": "Discussion"
        },
        {
            "endOffset": 21641,
            "parents": [],
            "secId": "s0065",
            "sentence": "The present study reports the novel observation that substituting Glu at position 3 of 2 OXM-like dual analogues caused a significant increase in body weight in a rat model, without altering food intake.",
            "startOffset": 21438,
            "title": "Discussion"
        },
        {
            "endOffset": 13476,
            "parents": [],
            "secId": "s0005",
            "sentence": "Therefore Glu-3 OXM analogues are not a suitable tool to investigate the effects of OXM-like dual analogues in a rat model.",
            "startOffset": 13353,
            "title": "Introduction"
        },
        {
            "endOffset": 24514,
            "parents": [],
            "secId": "s0070",
            "sentence": "Therefore Glu-3 OXM-like analogues are unsuitable tools to investigate the effects of OXM analogue activity in a rat model.",
            "startOffset": 24391,
            "title": "Conclusions"
        },
        {
            "endOffset": 24640,
            "parents": [],
            "secId": "s0075",
            "sentence": "The authors have indicated that they have no conflicts of interest regarding the content of this article.",
            "startOffset": 24535,
            "title": "Conflicts of Interest"
        },
        {
            "endOffset": 20453,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "A 30-nM dose of OXME3 increased cAMP levels by 9% compared with glucagon stimulation alone (Figure 3C).",
            "startOffset": 20350,
            "title": "In vitro"
        },
        {
            "endOffset": 11454,
            "parents": [],
            "secId": "s0005",
            "sentence": "The dual agonist properties of OXM make investigating its mechanism(s) of action difficult.",
            "startOffset": 11363,
            "title": "Introduction"
        },
        {
            "endOffset": 13149,
            "parents": [],
            "secId": "s0005",
            "sentence": "The 2 Glu-3 analogues OXM14E3 and OXM15E3 were chosen for investigation because they increased body weight in a pilot experiment and had similar conservative amino acid substitutions and pharmacokinetic profiles.",
            "startOffset": 12937,
            "title": "Introduction"
        },
        {
            "endOffset": 24140,
            "parents": [],
            "secId": "s0065",
            "sentence": "Therefore the relevance of the findings with Pro-3 GIP analogues to the present study is unclear.",
            "startOffset": 24043,
            "title": "Discussion"
        },
        {
            "endOffset": 22106,
            "parents": [],
            "secId": "s0065",
            "sentence": "This suggests that the Glu-3 OXM analogues may be partial agonists that can also act as competitive antagonists in vitro, despite reduced rat GCGr binding affinity.",
            "startOffset": 21942,
            "title": "Discussion"
        },
        {
            "endOffset": 21770,
            "parents": [],
            "refoffsets": {
                "bib6": {
                    "endOffset": 21698,
                    "startOffset": 21695
                },
                "bib7": {
                    "endOffset": 21698,
                    "startOffset": 21695
                }
            },
            "secId": "s0065",
            "sentence": "In line with previous findings at the mouse receptor,6,7 in vitro activity at the rat GCGr was diminished by Glu-3 substitution.",
            "startOffset": 21642,
            "title": "Discussion"
        },
        {
            "endOffset": 12739,
            "parents": [],
            "secId": "s0005",
            "sentence": "Several equivalent Glu-3 analogues were also designed to investigate the contribution of GCGr and GLP-1r activity to the effects of the OXM-like dual analogues.",
            "startOffset": 12579,
            "title": "Introduction"
        },
        {
            "endOffset": 16508,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Cells were serum starved in DMEM +1% antibiotic for 1 hour before 30 minutes\u2019 incubation at room temperature with peptide concentrations diluted in serum-free DMEM with 1 mM IBMX (Sigma-Aldrich, Dorset, United Kingdom).",
            "startOffset": 16289,
            "title": "In vitro cyclic adenosine monophosphate (cAMP) accumulation"
        },
        {
            "endOffset": 20222,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Concentrations of 3 and 30 nM of OXM14E3 and OXM15E3 increased cAMP levels compared with glucagon stimulation alone (OXM14E3 30 nM: 155% increase, OXM15E3 30nM: 214% increase) (Figure 3A-B).",
            "startOffset": 20032,
            "title": "In vitro"
        },
        {
            "endOffset": 21941,
            "parents": [],
            "secId": "s0065",
            "sentence": "Interestingly, glucagon-mediated activation of the rat GCGr in vitro was reduced by the lower concentrations of the Glu-3 analogues tested, including Glu-3 of native OXM.",
            "startOffset": 21771,
            "title": "Discussion"
        },
        {
            "endOffset": 24042,
            "parents": [],
            "refoffsets": {
                "bib15": {
                    "endOffset": 23957,
                    "startOffset": 23955
                }
            },
            "secId": "s0065",
            "sentence": "Human GIP has several different residues compared with rat and mouse GIP,15 whereas the amino acid sequences of glucagon and OXM are identical in the 3 species.",
            "startOffset": 23882,
            "title": "Discussion"
        }
    ],
    "docId": "S0011393X15000156",
    "metadata": {
        "asjc": [
            "2736",
            "3004"
        ],
        "authors": [
            {
                "email": null,
                "first": "Samantha L.",
                "initial": "S.L.",
                "last": "Price"
            },
            {
                "email": null,
                "first": "James S.",
                "initial": "J.S.",
                "last": "Minnion"
            },
            {
                "email": "s.bloom@imperial.ac.uk",
                "first": "Stephen R.",
                "initial": "S.R.",
                "last": "Bloom"
            }
        ],
        "doi": "10.1016/j.curtheres.2015.10.003",
        "firstpage": "111",
        "issn": "0011393X",
        "keywords": [
            "Analogue",
            "Body weight",
            "Glucagons",
            "Oxyntomodulin"
        ],
        "lastpage": "115",
        "openaccess": "Full",
        "pub_year": 2015,
        "subjareas": [
            "MEDI",
            "PHAR"
        ],
        "title": "Investigating the Glucagon Receptor and Glucagon-Like Peptide 1 Receptor Activity of Oxyntomodulin-Like Analogues in Male Wistar Rats"
    }
}